Last reviewed · How we verify
DE-108
DE-108 is a small molecule that inhibits Rho-associated protein kinase (ROCK) to reduce intraocular pressure by decreasing aqueous humor outflow resistance.
DE-108 is a small molecule that inhibits Rho-associated protein kinase (ROCK) to reduce intraocular pressure by decreasing aqueous humor outflow resistance. Used for Glaucoma and ocular hypertension.
At a glance
| Generic name | DE-108 |
|---|---|
| Also known as | Levofloxacin |
| Sponsor | Santen Pharmaceutical Co., Ltd. |
| Drug class | ROCK inhibitor |
| Target | ROCK (Rho-associated coiled-coil-containing protein kinase) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
DE-108 works as a ROCK inhibitor, which relaxes the trabecular meshwork and Schlemm's canal tissues in the eye, thereby improving aqueous humor drainage and lowering intraocular pressure. This mechanism is distinct from traditional glaucoma therapies and represents a novel approach to managing elevated intraocular pressure in glaucoma and ocular hypertension patients.
Approved indications
- Glaucoma and ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Ocular discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DE-108 CI brief — competitive landscape report
- DE-108 updates RSS · CI watch RSS
- Santen Pharmaceutical Co., Ltd. portfolio CI